1. SARS-CoV-2 infection leads to cardiac pericyte loss, fibrosis, cardiomyocyte hypertrophy, and diastolic dysfunction
- Author
-
Johan Neyts, Stephane Heymans, Marleen Lox, Tschoepe C, Linthout Sv, Peter Verhamme, Steven J. Simmonds, Raman J, Margo Daems, Elizabeth A. V. Jones, Laurens Liesenborghs, Robbert Boudewijns, Geuens N, and Ilona Cuijpers
- Subjects
medicine.medical_specialty ,medicine.anatomical_structure ,Fibrosis ,business.industry ,Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) ,Internal medicine ,medicine ,Cardiology ,Diastole ,Cardiomyocyte hypertrophy ,Pericyte ,medicine.disease ,business - Abstract
Recovered COVID19 patients often display cardiac dysfunction, even after a relatively mild infection. Here, we present the first histological description of cardiac SARS-CoV-2 infection. Within the heart, the ACE2 receptor is mostly expressed by pericytes. Using a COVID19 hamster model, we demonstrate SARS-CoV-2 is replicating in pericytes, and reduced pericyte density is present after infection. In healthy animals, pericytes recover; however, when metabolic comorbidities are present, they fail to recover. These latter animals present with cardiac fibrosis, cardiomyocyte hypertrophy, and early signs of diastolic dysfunction, resembling HFpEF. Biopsies from recovered COVID19 patients showed similar results, with pericyte loss being present.
- Published
- 2020
- Full Text
- View/download PDF